Trevi Therapeutics’ (TRVI) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $12.50 price objective on the stock. HC Wainwright also issued estimates for Trevi Therapeutics’ Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at ($0.31) EPS.

Other research analysts also recently issued reports about the stock. Needham & Company LLC cut their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $9.00 to $29.00 in a report on Monday, March 10th. D. Boral Capital reiterated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Finally, Oppenheimer increased their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Seven analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $17.56.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $6.47 on Wednesday. The stock has a market capitalization of $497.32 million, a PE ratio of -14.70 and a beta of 0.90. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.39. The business’s fifty day moving average price is $4.60 and its 200-day moving average price is $3.75.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. As a group, equities analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Insider Buying and Selling at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 24.37% of the company’s stock.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds have recently bought and sold shares of the stock. Summit Investment Advisors Inc. lifted its holdings in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after acquiring an additional 2,894 shares during the last quarter. Bank of New York Mellon Corp raised its position in Trevi Therapeutics by 2.1% during the fourth quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock valued at $578,000 after purchasing an additional 2,935 shares in the last quarter. SG Americas Securities LLC lifted its stake in Trevi Therapeutics by 14.5% during the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after purchasing an additional 3,387 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Trevi Therapeutics by 21.2% in the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company’s stock worth $97,000 after purchasing an additional 4,133 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Trevi Therapeutics by 32.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company’s stock worth $104,000 after purchasing an additional 6,119 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.